Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study

C L Leen, E M Dunbar, M E Ellis, B K Mandal

Research output: Contribution to journalArticlepeer-review

Abstract

Fluconazole 50 mg daily for 14-28 days was effective in the treatment of patients with AIDS and AIDS-related complex with severe oropharyngeal and oesophageal candidiasis. Of 24 patients entered, 17 (81%), including seven with oesophageal candidiasis, were clinically cured and two (9.5%) improved at the end of treatment. Following clinical cure, 14 patients were entered into the double-blind phase of the study, where fluconazole (150 mg) or placebo capsules were given once weekly. Treatment was double blind. Fluconazole 150 mg once weekly was found to be effective in maintaining patients both clinically and mycologically free of oropharyngeal candidiasis.
Original languageEnglish
Pages (from-to)55-60
Number of pages6
JournalJournal of Infection
Volume21
Issue number1
Publication statusPublished - Jul 1990

Keywords

  • AIDS-Related Complex
  • Acquired Immunodeficiency Syndrome
  • Adult
  • Candidiasis, Oral
  • Clinical Trials as Topic
  • Double-Blind Method
  • Esophageal Neoplasms
  • Fluconazole
  • Humans
  • Male
  • Middle Aged
  • Pharyngeal Diseases
  • Recurrence
  • Remission Induction
  • Risk Factors
  • Time Factors

Fingerprint Dive into the research topics of 'Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study'. Together they form a unique fingerprint.

Cite this